TriSalus Life Sciences Partners with Geo-Med to Improve Liver Cancer Treatment for Veterans

TriSalus Life Sciences Partners with Geo-Med to Enhance Liver Cancer Treatment for Veterans

TriSalus Life Sciences Inc. has entered a strategic partnership with Geo-Med, LLC, a certified Service-Disabled Veteran-Owned Small Business, to improve access to its TriNav Infusion System across U.S. Department of Veterans Affairs (VA) medical centers. This collaboration specifically targets veterans diagnosed with hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. Studies indicate that veterans experience a higher incidence of HCC compared to the general population, making this partnership particularly relevant. The TriNav Infusion System leverages TriSalus's proprietary Pressure-Enabled Drug Delivery™ (PEDD™) technology, which enhances drug delivery directly to tumors while minimizing adverse effects on surrounding healthy tissues.

Mary Szela, CEO of TriSalus, highlights the significance of this partnership in expanding treatment options for veterans. The collaboration aligns with the company's mission to improve patient outcomes through innovative drug delivery technologies. By making the TriNav Infusion System more accessible, TriSalus aims to provide veterans with a more effective treatment for HCC. The partnership underscores the commitment of both organizations to address the unique needs of veterans, ensuring they receive the advanced medical care they deserve.

Geo-Med's expertise in procurement for the VA and U.S. Department of Defense (DOD) positions them as a valuable ally in this endeavor. Mike Locke, CEO of Geo-Med, expresses pride in joining forces with TriSalus, emphasizing their shared goal of delivering cutting-edge technology to veterans facing aggressive liver cancer. This collaboration not only enhances treatment access but also seeks to overcome the anatomical challenges associated with traditional infusion methods, thereby improving the overall delivery of therapeutics for those in need.

In addition to the TriNav Infusion System, TriSalus's platform includes FDA-cleared devices for various therapeutic applications, showcasing the company’s commitment to addressing multiple cancer types. This partnership represents a significant step forward in meeting the healthcare needs of veterans, particularly as they face the challenges associated with aggressive cancers like HCC. TriSalus's innovative approach, combined with Geo-Med's procurement capabilities, promises to advance the standards of care for this underserved population.

Ultimately, this strategic collaboration not only benefits veterans but also positions TriSalus as a leader in oncology-focused drug delivery systems, reinforcing its commitment to improving patient care and outcomes.